A one-year prospective study of bacteremia was carried out at a Swedish university hospital. Blood cultures were taken in 6.3% of all patients admitted to the hospital. 148 episodes of bacteremia were recorded in 142 patients, 59% of whom were males. The mean incidence of bacteremia was 4.3 episodes per 1,000 admissions. The incidence of contamination was 1.3%. Malignancy and urinary tract disorders were the most common diagnoses and surgical intervention, central venous catheters and cytostatic drugs the most common predisposing factors. The ratio of hospital to community-acquired bacteremia was 1.3:1. The fatality rate was 12.7%. Gram-negative rods belonging to the Enterobacteriaceae were the most common pathogens, followed by Staphylococcus aureus and Staphylococcus epidermidis. The antibiotic sensitivity pattern of the causative bacteria was quite favorable. No S. aureus strains were resistant to isoxazolyl penicillins or gentamicin. No Klebsiella strain and only one Escherichia coli strain was resistant to gentamicin. The results were compared to a one-year retrospective study carried out in the same hospital five years ago. The incidence of bacteremia had not increased between the two studies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/BF01645950 | DOI Listing |
Scand J Trauma Resusc Emerg Med
January 2025
Anaesthesiology and Intensive Care, Department of Surgical Sciences, Uppsala University, 715 85, Uppsala, Sweden.
Background: Unit-to-unit transfer of critically ill patients infers hazards that may cause adverse events. Circumstantial factors associated with mortality after intensive care include days in the ICU, night-time or weekend discharge and capacity transfer as compared to other reasons for transfer. Distance travelled may also constitute an indirect risk.
View Article and Find Full Text PDFBMC Health Serv Res
January 2025
Institute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Introduction: The COVID-19 pandemic forced leaders and employees in health care services to take difficult decisions to manage risks associated with employee health and the organizations' functioning. This study aims to identify the changes in employee working routines, job demands, and job resources within Swedish maternal healthcare during the COVID-19 pandemic, and how these changes affected workload and health.
Methods: Data were derived from the longitudinal COPE Staff study involving midwives and physicians within maternal healthcare.
Nature
January 2025
International Union for the Conservation of Nature (IUCN) Conservation Genetics Specialist Group (CGSG), .
Mitigating loss of genetic diversity is a major global biodiversity challenge. To meet recent international commitments to maintain genetic diversity within species, we need to understand relationships between threats, conservation management and genetic diversity change. Here we conduct a global analysis of genetic diversity change via meta-analysis of all available temporal measures of genetic diversity from more than three decades of research.
View Article and Find Full Text PDFBMJ Open
January 2025
Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden.
Objective: Delayed neurocognitive recovery, previously known as postoperative cognitive dysfunction, is a common complication affecting older adults after surgery. This study aims to address the knowledge gap in postoperative neurocognitive recovery by exploring the relationship between subjective experiences, performance-based measurements, and blood biomarkers.
Design: Mixed-methods study with a convergent parallel (QUAL+quan) design.
RMD Open
January 2025
Clinical Epidemiology Division, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden.
Objective: To compare work loss after starting tumour necrosis factor inhibitors (TNFi), rituximab, abatacept or tocilizumab in patients with rheumatoid arthritis (RA).
Methods: We used data from the Swedish Rheumatology Quality Register to identify patients aged 19-62 years who were treated with TNFi (n=15 093), rituximab (n=2123), abatacept (n=1877) or tocilizumab (n=1720) between 2007 and 2020. Data on work loss (0-365 days per year) from sick leave and disability pension were retrieved from linkage to the Social Insurance Agency.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!